Systematic review and meta-analysis on the effects of thiopurines on birth outcomes from female and male patients with inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 19, Issue 1, 2013, Pages 15-22

  Akbari, Mona ^a   Shah, Sveta ^a   Velayos, Fernando S ^b   Mahadevan, Uma ^b   Cheifetz, Adam S ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Birth outcomes; Congenital abnormalities; Inflammatory bowel disease; Mercaptopurine; Thiopurines

Indexed keywords

MERCAPTOPURINE; TUMOR NECROSIS FACTOR ANTIBODY;

CONGENITAL CATARACT; CONGENITAL HYDROCEPHALUS; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG EXPOSURE; ENCEPHALOCELE; ENTERITIS; HEART ATRIUM SEPTUM DEFECT; HEART VENTRICLE SEPTUM DEFECT; HOSPITALIZATION; HUMAN; LOW BIRTH WEIGHT; META ANALYSIS; PREGNANCY OUTCOME; PREMATURE LABOR; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW;

6-MERCAPTOPURINE; AZATHIOPRINE; CONGENITAL ABNORMALITIES; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT, LOW BIRTH WEIGHT; INFANT, NEWBORN; INFLAMMATORY BOWEL DISEASES; MALE; META-ANALYSIS AS TOPIC; ODDS RATIO; PREGNANCY; PREGNANCY COMPLICATIONS; PREMATURE BIRTH; PROGNOSIS;

EID: 84873284779     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.22948     Document Type: Review

References (68)

1. Prefontaine E, Macdonald JK, Sutherland LR. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2010:CD000545.
2. Ardizzone S, Maconi G, Russo A, et al. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut. 2006;55:47-53.
3. Candy S, Wright J, Gerber M, et al. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut. 1995;37: 674-678.
4. Hawthorne AB, Logan RF, Hawkey CJ, et al. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ. 1992;305:20-22.
5. Kirk AP, Lennard-Jones JE. Controlled trial of azathioprine in chronic ulcerative colitis. Br Med J (Clin Res Ed). 1982;284:1291-1292.
6. Lemann M, Mary JY, Colombel JF, et al. A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine. Gastroenterology. 2005;128:1812-1818.
7. Paoluzi OA, Pica R, Marcheggiano A, et al. Azathioprine or methotrexate in the treatment of patients with steroid-dependent or steroidresistant ulcerative colitis: results of an open-label study on efficacy and tolerability in inducing and maintaining remission. Aliment Phar macol Ther. 2002;16:1751-1759.
8. Vilien M, Dahlerup JF, Munck LK, et al. Randomized controlled aza thioprine withdrawal after more than two years treatment in Crohn's disease: increased relapse rate the following year. Aliment Pharmacol Ther. 2004;19:1147-1152.
9. Timmer A, McDonald JW, Macdonald JK. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2007:CD000478.
10. Mountifield RE, Prosser R, Bampton P, et al. Pregnancy and IBD treatment: this challenging interplay from a patients' perspective. J Crohns Colitis. 2010;4:176-182.
11. Julsgaard M, Norgaard M, Hvas CL, et al. Self-reported adherence to medical treatment prior to and during pregnancy among women with ulcerative colitis. Inflamm Bowel Dis. 2011;17:1573-1580.
12. Norgard B, Pedersen L, Fonager K, et al. Azathioprine, mercaptopurine and birth outcome: a population-based cohort study. Aliment Pharmacol Ther. 2003;17:827-834.
13. Ostrer H, Stamberg J, Perinchief P. Two chromosome aberrations in the child of a woman with systemic lupus erythematosus treated with azathioprine and prednisone. Am J Med Genet. 1984;17:627-632.
14. Davison JM, Dellagrammatikas H, Parkin JM. Maternal azathioprine therapy and depressed haemopoiesis in the babies of renal allograft patients. Br J Obstet Gynaecol. 1985;92:233-239.
15. Cote CJ, Meuwissen HJ, Pickering RJ. Effects on the neonate of prednisone and azathioprine administered to the mother during pregnancy. J Pediatr. 1974;85:324-328.
16. Dewitte DB, Buick MK, Cyran SE, et al. Neonatal pancytopenia and severe combined immunodeficiency associated with antenatal administration of azathioprine and prednisone. J Pediatr. 1984;105:625-628.
17. Pirson Y, Van Lierde M, Ghysen J, et al. Retardation of fetal growth in patients receiving immunosuppressive therapy. N Engl J Med. 1985;313:328.
18. Ben-Neriah Z, Ackerman Z. WAGR syndrome in a baby-the result of 6-MP treatment in a father affected by Crohn's disease? Am J Gas troenterol. 2001;96:251.
19. Cornish J, Tan E, Teare J, et al. A meta-analysis on the influence of inflammatory bowel disease on pregnancy. Gut. 2007;56:830-837.
20. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available at http://www.ohri.ca/ programs/clinical-epidemiology/oxford.asp
21. Cook DA, Levinson AJ, Garside S. Method and reporting quality in health professions education research: a systematic review. Med Educ. 2010;45:227-238.
22. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283:2008-2012.
23. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62:1006-1012.
24. Dersimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-188.
25. Rosner B. Fundamentals of Biostatistics. 4th ed. Belmont, CA: Wadsworth Publishing; 1995.
26. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539-1558.
27. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629-634.
28. Naganuma M, Kunisaki R, Yoshimura N, et al. Conception and pregnancy outcome in women with inflammatory bowel disease: a multi-centre study from Japan. J Crohns Colitis. 2011;5:317-323.
29. Bengtson MB, Solberg IC, Aamodt G, et al. Relationships between inflammatory bowel disease and perinatal factors: both maternal and paternal disease are related to preterm birth of offspring. Inflamm Bowel Dis. 2010;16:847-855.
30. Bortoli A, Pedersen N, Duricova D, et al. Pregnancy outcome in inflammatory bowel disease: prospective European case-control ECCO-Epi-Com study, 2003-2006. Aliment Pharmacol Ther. 2010;34:724-734.
31. Molnar T, Farkas K, Nagy F, et al. Pregnancy outcome in patients with inflammatory bowel disease according to the activity of the disease and the medical treatment: a case-control study. Scand J Gastroenterol. 2010;45:1302-1306.
32. Moskovitz DN, Bodian C, Chapman ML, et al. The effect on the fetus of medications used to treat pregnant inflammatory bowel-disease patients. Am J Gastroenterol. 2004;99:656-661.
33. Raatikainen K, Mustonen J, Pajala MO, et al. The effects of pre-and postpregnancy inflammatory bowel disease diagnosis on birth outcomes. Aliment Pharmacol Ther. 2010;33:333-339.
34. Bortoli A, Saibeni S, Tatarella M, et al. Pregnancy before and after the diagnosis of inflammatory bowel diseases: retrospective case-control study. J Gastroenterol Hepatol. 2007;22:542-549.
35. Baiocco PJ, Korelitz BI. The influence of inflammatory bowel disease and its treatment on pregnancy and fetal outcome. J Clin Gastroenterol. 1984;6:211-216.
36. Mahadevan U, Sandborn WJ, Li DK, et al. Pregnancy outcomes in women with inflammatory bowel disease: a large community-based study from Northern California. Gastroenterology. 2007;133:1106-1112.
37. Hudson M, Flett G, Sinclair TS, et al. Fertility and pregnancy in inflammatory bowel disease. Int J Gynaecol Obstet. 1997;58:229-237.
38. Bouhnik Y, Lemann M, Mary JY, et al. Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet. 1996;347:215-219.
39. Oefferlbauer-Ernst A, Reinisch W, Miehsler W, et al. Healthy offspring in parents both receiving thiopurines. Gastroenterology. 2004;126:628.
40. Alstead EM, Ritchie JK, Lennard-Jones JE, et al. Safety of azathioprine in pregnancy in inflammatory bowel disease. Gastroenterology. 1990;99: 443-446.
41. Present DH, Meltzer SJ, Krumholz MP, et al. 6-Mercaptopurine in the management of inflammatory bowel disease: short-and long-term toxicity. Ann Intern Med. 1989;111:641-649.
42. Sato A, Naganuma M, Asakura K, et al. Conception outcomes and opinions about pregnancy for men with inflammatory bowel disease. J Crohns Colitis. 2010;4:183-188.
43. Goldstein LH, Dolinsky G, Greenberg R, et al. Pregnancy outcome of women exposed to azathioprine during pregnancy. Birth Defects Res A Clin Mol Teratol. 2007;79:696-701.
44. Norgard B, Pedersen L, Jacobsen J, et al. The risk of congenital abnormalities in children fathered by men treated with azathioprine or mercaptopurine before conception. Aliment Pharmacol Ther. 2004;19:679-685.
45. Angelberger S, Reinisch W, Messerschmidt A, et al. Long-term follow-up of babies exposed to azathioprine in utero and via breastfeeding. J Crohns Colitis. 2011;5:95-100.
46. Zlatanic J, Korelitz BI, Rajapakse R, et al. Complications of pregnancy and child development after cessation of treatment with 6-mercaptopurine for inflammatory bowel disease. J Clin Gastroenterol. 2003;36:303-309.
47. Norgard B, Pedersen L, Christensen LA, et al. Therapeutic drug use in women with Crohn's disease and birth outcomes: a Danish nationwide cohort study. Am J Gastroenterol. 2007;102:1406-1413.
48. Langagergaard V, Pedersen L, Gislum M, et al. Birth outcome in women treated with azathioprine or mercaptopurine during pregnancy: A Danish nationwide cohort study. Aliment Pharmacol Ther. 2007;25:73-81.
49. Francella A, Dyan A, Bodian C, et al. The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retro spective cohort study. Gastroenterology. 2003;124:9-17.
50. Coelho J, Beaugerie L, Colombel JF, et al. Pregnancy outcome in patients with inflammatory bowel disease treated with thiopurines: cohort from the CESAME study. Gut. 2010;60:198-203.
51. Cleary BJ, Kallen B. Early pregnancy azathioprine use and pregnancy outcomes. Birth Defects Res A Clin Mol Teratol. 2009;85:647-654.
52. Shim L, Eslick GD, Simring AA, et al. The effects of azathioprine on birth outcomes in women with inflammatory bowel disease (IBD). J Crohns Colitis. 2011;5:234-238.
53. Teruel C, Lopez-San Roman A, Bermejo F, et al. Outcomes of pregnancies fathered by inflammatory bowel disease patients exposed to thiopurines. Am J Gastroenterol. 2010;105:2003-2008.
54. Rajapakse RO, Korelitz BI, Zlatanic J, et al. Outcome of pregnancies when fathers are treated with 6-mercaptopurine for inflammatory bowel disease. Am J Gastroenterol. 2000;95:684-688.
55. Bush MC, Patel S, Lapinski RH, et al. Perinatal outcomes in inflammatory bowel disease. J Matern Fetal Neonatal Med. 2004;15:237-241.
56. Fedorkow DM, Persaud D, Nimrod CA. Inflammatory bowel disease: a controlled study of late pregnancy outcome. Am J Obstet Gynecol. 1989;160:998-1001.
57. Morales M, Berney T, Jenny A, et al. Crohn's disease as a risk factor for the outcome of pregnancy. Hepatogastroenterology. 2000;47: 1595-1598.
58. Norgard B, Hundborg HH, Jacobsen BA, et al. Disease activity in pregnant women with Crohn's disease and birth outcomes: a regional Danish cohort study. Am J Gastroenterol. 2007;102:1947-1954.
59. Reddy D, Murphy SJ, Kane SV, et al. Relapses of inflammatory bowel disease during pregnancy: in-hospital management and birth outcomes. Am J Gastroenterol. 2008;103:1203-1209.
60. Koretz RL. Methods of meta-analysis: an analysis. Curr Opin Clin Nutr Metab Care. 2002;5:467-474.
61. Kornfeld D, Cnattingius S, Ekbom A. Pregnancy outcomes in women with inflammatory bowel disease-a population-based cohort study. Am J Obstet Gynecol. 1997;177:942-946.
62. Fonager K, Sorensen HT, Olsen J, et al. Pregnancy outcome for women with Crohn's disease: a follow-up study based on linkage between national registries. Am J Gastroenterol. 1998;93:2426-2430.
63. Elbaz G, Fich A, Levy A, et al. Inflammatory bowel disease and preterm delivery. Int J Gynaecol Obstet. 2005;90:193-197.
64. Baird DD, Narendranathan M, Sandler RS. Increased risk of preterm birth for women with inflammatory bowel disease. Gastroenterology. 1990;99: 987-994.
65. Dominitz JA, Young JC, Boyko EJ. Outcomes of infants born to mothers with inflammatory bowel disease: a population-based cohort study. Am J Gastroenterol. 2002;97:641-648.
66. Stephansson O, Larsson H, Pedersen L, et al. Crohn's disease is a risk factor for preterm birth. Clin Gastroenterol Hepatol. 2010;8:509-515.
67. Stephansson O, Larsson H, Pedersen L, et al. Congenital abnormalities and other birth outcomes in children born to women with ulcerative colitis in Denmark and Sweden. Inflamm Bowel Dis. 2011;17:795-801.
68. Malgarinos G, Gikas A, Delicha E, et al. Pregnancy and inflammatory bowel disease: a prospective case-control study. Rev Med Chir Soc Med Nat Iasi. 2007;111:613-619.